- « Previous
- Clinical Pharmacology
- Next »
Privigen
CLINICAL PHARMACOLOGY
Privigen
Mechanism of Action
Treatment of Primary Immunodeficiency
Privigen™ contains a broad spectrum of antibody specificities. Appropriate doses of Privigen™ should restore abnormally low IgG levels to the normal range.
Treatment of Chronic Immune Thrombocytopenic Purpura
The mechanism of action of immunoglobulins in the treatment of chronic ITP is not fully understood. One possible mechanism may be the inhibition of the elimination of autoantibody-reacted platelets from the blood circulation by IgG-induced Fc-receptor blockade of phagocytes.17 Another proposed mechanism is the down-regulation of platelet autoantibody-producing B cells by anti-idiotypic antibodies in IGIV.18
Pharmacokinetics
Treatment of Primary Immunodeficiency
In the clinical study assessing the efficacy and safety of Privigen™ in 80 subjects with PI (see CLINICAL STUDIES), serum concentrations of total IgG and IgG subclasses were measured in 25 subjects (ages 13 to 69) following the 7th infusion for the 3 subjects on the 3-week dosing interval and following the 5th infusion for the 22 subjects on the 4-week dosing interval. After the infusion, blood samples were taken until Day 21 and Day 28 for the 3-week and 4-week dosing intervals, respectively.
Table 4 summarizes the pharmacokinetic parameters of Privigen™, measured as serum concentrations of total IgG.
Table 4: Pharmacokinetic Parameters of Privigen™ in Subjects with PI
| Parameter | 3-Week Dosing Interval (n=3) |
4-Week Dosing Interval (n=22) |
||
| Mean (SD) |
Median (Range) |
Mean (SD) |
Median (Range) |
|
| Cmax (peak, mg/dL) | 2,550 | 2,340 | 2,260 | 2,340 |
| (400) | (2,290-3,010) | (530) | (1,040-3,460) | |
| Cmin (trough, mg/dL) | 1,230 | 1,200 | 1,000 | 1,000 |
| (230) | (1,020-1,470) | (200) | (580-1,360) | |
| t½ (days) | 27.6 | 27.8 | 45.4 | 37.3 |
| (5.9) | (21.6-33.4) | (18.5) | (20.6-96.6) | |
| AUC0-t (day × mg/dL)* | 32,820 | 29,860 | 36,390 | 36,670 |
| (6,260) | (28,580-40,010) | (5,950) | (19,680-44,340) | |
| Clearance (mL/day/kg)* | 1.3 | 1.3 | 1.3 | 1.3 |
| (0.1) | (1.1-1.4) | (0.3) | (0.9-2.1) | |
| Cmax, maximum serum concentration; Cmin,
trough (minimum level) serum concentration; t½, elimination half-life;
AUC0-t, area under the curve from 0 hour to last sampling time.
* Calculated by log-linear trapezoidal rule. |
||||
Generic Name: Immune Globulin Intravenous
- « Previous
- Clinical Pharmacology
- Next »
Exercise for Urinary Incontinence
Like millions, Mary Lou Retton has urinary incontinence. There are no medications but pelvic muscle exercises often help. See more WebMD Videos »
WebMD Daily
Get breaking medical news.
